Real-world utilization and effectiveness of long-acting Ccbotegravir + rilpivirine in virologically suppressed treatment experienced individuals in Europe: data from COMBINE-2 cohort study

AUTHORS

A. Pozniak¹, G. Sridhar², L. Assoumou^1,3, L. Piroth⁴, D. Braun⁵, C. Fletcher⁶, A. Duffy⁶, L. Ragone², A. Shah⁷, J. van Wyk⁸, V. Vannappagari²


INSTITUTIONS

¹The European Treatment Network for HIV, Hepatitis and Global Infectious Diseases (NEAT-ID), London, United Kingdom, ²ViiV Healthcare, Durham, United States, ³Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France, ⁴CHU Dijon-Bourgogne, Dijon Cedex, France, ⁵Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁶Research Organization (KC) Ltd., London, United Kingdom, ⁷GlaxoSmithKline, Brentford, Middlesex, United Kingdom, ⁸ViiV Healthcare, London, England, United Kingdom